"GTC, with an approved drug—and consequently an approved technology platform—ought to be worth as least as much as GlycoFi based on any rational valuation analysis."
You would think. However, MRK is going after more lucrative markets than ATryn. I think GTCB's stock price is clouded by focus on ATryn's small market size (for the approved indication, at least). Could GTCB perhaps have failures garnering regulatory approval of drugs that have competing products already in the marketplace that are produced in bioreactors? I'm not sure we know the answer to this important question with certainty, although I suppose the same question applies to humanized yeast!
News 
Market Data 
Discover 
